Literature DB >> 11881743

Huntington's disease: new hope for therapeutics.

C T McMurray1.   

Abstract

Huntington's disease (HD) is one of eight progressive neurodegenerative disorders in which the underlying mutation is a CAG expansion encoding a polyglutamine tract. There are currently no cures or even effective therapies for HD. Effective strategies have remained elusive because little is known about either the mechanisms of expansion or the mechanism of polyglutamine-mediated neuronal death. However, recent advances in understanding the basic mechanisms of expansion and toxicity have renewed hope that a therapeutic strategy might someday be possible. Strategies effective in the treatment of HD are likely to be relevant in the treatment of a range of neurological and neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11881743     DOI: 10.1016/s0166-2236(00)01997-4

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  9 in total

1.  Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation.

Authors:  Francisca Pérez-Severiano; Abel Santamaría; José Pedraza-Chaverri; Omar N Medina-Campos; Camilo Ríos; José Segovia
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

2.  Incidence and persistence of 8-oxo-7,8-dihydroguanine within a hairpin intermediate exacerbates a toxic oxidation cycle associated with trinucleotide repeat expansion.

Authors:  Daniel A Jarem; Nicole R Wilson; Kelly M Schermerhorn; Sarah Delaney
Journal:  DNA Repair (Amst)       Date:  2011-07-02

3.  Potential drugs and methods for preventing or delaying the progression of Huntington's disease.

Authors:  Youssef Sari
Journal:  Recent Pat CNS Drug Discov       Date:  2011-05-01

4.  Geraniol Protects Against the Protein and Oxidative Stress Induced by Rotenone in an In Vitro Model of Parkinson's Disease.

Authors:  Karamkolly R Rekha; Ramu Inmozhi Sivakamasundari
Journal:  Neurochem Res       Date:  2018-08-23       Impact factor: 3.996

5.  Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Authors:  Onintza Sagredo; Sara González; Ilia Aroyo; María Ruth Pazos; Cristina Benito; Isabel Lastres-Becker; Juan P Romero; Rosa M Tolón; Raphael Mechoulam; Emmanuel Brouillet; Julián Romero; Javier Fernández-Ruiz
Journal:  Glia       Date:  2009-08-15       Impact factor: 7.452

6.  Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy.

Authors:  Youssef Sari
Journal:  Int J Biomed Sci       Date:  2011-06

7.  A role for voltage-dependent anion channel Vdac1 in polyglutamine-mediated neuronal cell death.

Authors:  Tanay Ghosh; Neeraj Pandey; Arindam Maitra; Samir K Brahmachari; Beena Pillai
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240

8.  The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.

Authors:  S Valdeolivas; M R Pazos; T Bisogno; F Piscitelli; F A Iannotti; M Allarà; O Sagredo; V Di Marzo; J Fernández-Ruiz
Journal:  Cell Death Dis       Date:  2013-10-17       Impact factor: 8.469

Review 9.  Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches.

Authors:  Rashad Hussain; Hira Zubair; Sarah Pursell; Muhammad Shahab
Journal:  Brain Sci       Date:  2018-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.